Dyslipaemia;Dislipidemias

Revista Brasileira de Medicina

Volumn 62, Issue 5, 2005, Pages 174-180

  Faludi, André Arpad ^a   Zats, Henri Paulo ^a,b   De Araújo, Daniel Branco ^b   Bertolami, Marcelo Chiara ^a,b  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Cholesterol; Dyslipaemia; Hypolipidaemic

Indexed keywords

ALPHA TOCOPHEROL; ANABOLIC AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; CAROTENOID; CHOLESTEROL; CIPROFIBRATE; CLOFIBRATE; COLESTYRAMINE; CONTRACEPTIVE AGENT; CORTICOSTEROID; DIURETIC AGENT; ETOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLAVONOID; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PRAVASTATIN; ROSUVASTATIN; SATURATED FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ADULT; AGED; ALCOHOLISM; CONSTIPATION; DIABETES MELLITUS; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; DYSPNEA; FEMALE; FLATULENCE; FLUSHING; HEART PALPITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; HYPERLIPIDEMIA; HYPOTHYROIDISM; LIFESTYLE; MALE; NAUSEA; NEPHROTIC SYNDROME; OBESITY; PHYSICAL ACTIVITY; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

EID: 21844463561     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
2. III Diretrizes Brasileiras sobre Dislipidemias. Arquivos Brasileiros de Cardiologia. 2001, v.77, Supl. III.
3. Martinez TLR. Manual de condutas Clínicas em Dislipidemias. 2003. Ed. Medline. Rio de Janeiro. P. 183-212.
4. Unilever Reseach Laboratories. Diet and Health News 1998; 2.
5. Catapano AL. Ezetimibe: A selective inhibitor of cholesterol absorption. Eur Heart J 2001; v. 3 (suppl E), P.E6-E10.
6. Van Heek M, Farley C, Compton DS, et al. Comparasion of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucoronide, SCH60663. Br J Pharmacol 2000; 129:1748-1754.
7. Ezzet F, Krishna G, Wexler DB et al. A population pharmacokinetic model that describes multiples peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001; 23:871-885.
8. Patrik JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002; 30:430-437.
9. Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies. Clin Ther 2001; 23:1209-1230.
10. Dujovne CA, Ettinger MP, Mark P, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002; 90:1092-97.
11. Staels et al. Mechanism of action of fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998; 10:2088-2093.
12. Chapman MJ. Pharmacology of fibrate. The American Journal of Medicine 1987; 83 (suppl 5B):21-25.
13. Diament J, Forti N, Giannini SD. Fibratos: semelhanças e diferenças. Rev Soc Cardiol Estado de São Paulo 1999; 1:83-91.
14. Tikkanen MJ. Fibric acid derivates. Curr Opin Lipidol 1992; 3:29-33.
15. Vu Dac n, Schoonjans K, Kosykh V, Dallongeville J, Fruchart J, Staels B, Auwerx J. Fibrates increase human apolipoprotein AII expression through activation of the peroxisome proliferators-activated receptor. J Clin Invest 1995; 96:741-750.
16. Berthou L et al. Opposite regulation of human versus mouse apolipoprotein AI by fibrates in human apo AI transgenic mice. J Clin Invest 1996; 97: 2408-2416.
17. Quintão ECR. Colesterol e Aterosclerose. 1992, Ed. Qualitymark, P.181-182.